CareDx (CDNA) Releases Quarterly Earnings Results
CareDx (NASDAQ:CDNA) announced its earnings results on Thursday. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.42), Morningstar.com reports. CareDx had a negative net margin of 121.92% and a negative return on equity of 108.99%. The company had revenue of $21.18 million during the quarter, compared to analysts’ expectations of $18.47 million. CareDx updated its FY 2018 guidance to EPS.
CareDx stock opened at $25.61 on Friday. The company has a current ratio of 2.16, a quick ratio of 1.83 and a debt-to-equity ratio of 0.46. CareDx has a 1-year low of $4.92 and a 1-year high of $30.15. The company has a market capitalization of $1.03 billion, a P/E ratio of -33.26 and a beta of 1.06.
In related news, insider Sasha King sold 11,500 shares of CareDx stock in a transaction that occurred on Friday, October 5th. The stock was sold at an average price of $24.60, for a total value of $282,900.00. Following the sale, the insider now directly owns 53,542 shares in the company, valued at $1,317,133.20. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, major shareholder Neil Gagnon sold 108,599 shares of CareDx stock in a transaction that occurred on Wednesday, October 31st. The shares were sold at an average price of $27.05, for a total value of $2,937,602.95. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 163,954 shares of company stock worth $4,187,359. Company insiders own 3.40% of the company’s stock.
Several research analysts have weighed in on the company. Craig Hallum reiterated a “buy” rating and issued a $40.00 target price on shares of CareDx in a research note on Friday. HC Wainwright reiterated a “neutral” rating and issued a $22.00 target price on shares of CareDx in a research note on Tuesday, September 18th. BidaskClub upgraded CareDx from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, August 14th. Zacks Investment Research downgraded CareDx from a “buy” rating to a “sell” rating in a research note on Wednesday, August 15th. Finally, Raymond James reiterated a “strong-buy” rating and issued a $30.00 target price on shares of CareDx in a research note on Tuesday, October 23rd. Two equities research analysts have rated the stock with a hold rating, two have given a buy rating and three have assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $29.60.
ILLEGAL ACTIVITY NOTICE: “CareDx (CDNA) Releases Quarterly Earnings Results” was first reported by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2018/11/10/caredx-cdna-releases-quarterly-earnings-results.html.
CareDx, Inc, a transplant diagnostics company, together with its subsidiaries, engages in the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients worldwide. It operates through two segments, Post-Transplant Diagnostics and Pre-Transplant Diagnostics.
Featured Story: Market Capitalization
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.